NYSE:ELAN

Elanco Animal Health Competitors

$32.24
-0.64 (-1.95 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.23
$33.32
50-Day Range
$27.85
$32.88
52-Week Range
$18.37
$34.81
Volume3.03 million shs
Average Volume3.88 million shs
Market Capitalization$15.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.86

Competitors

Elanco Animal Health (NYSE:ELAN) Vs. VRTX, REGN, TAK, ALXN, BGNE, and RPRX

Should you be buying ELAN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Elanco Animal Health, including Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), and Royalty Pharma (RPRX).

Vertex Pharmaceuticals (NASDAQ:VRTX) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Vertex Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals041612.86
Elanco Animal Health23702.42

Vertex Pharmaceuticals currently has a consensus price target of $293.4737, suggesting a potential upside of 37.85%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Elanco Animal Health.

Profitability

This table compares Vertex Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Elanco Animal Health-8.45%3.43%2.04%

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.63
Elanco Animal Health$3.07 billion4.96$67.90 million$1.0630.42

Vertex Pharmaceuticals has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Elanco Animal Health on 14 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Regeneron Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Elanco Animal Health23702.42

Regeneron Pharmaceuticals currently has a consensus price target of $656.3810, suggesting a potential upside of 30.66%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Elanco Animal Health.

Profitability

This table compares Regeneron Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Elanco Animal Health-8.45%3.43%2.04%

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.84$2.12 billion$21.4723.40
Elanco Animal Health$3.07 billion4.96$67.90 million$1.0630.42

Regeneron Pharmaceuticals has higher revenue and earnings than Elanco Animal Health. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Elanco Animal Health on 12 of the 14 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Takeda Pharmaceutical and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical02002.00
Elanco Animal Health23702.42

Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Takeda Pharmaceutical.

Profitability

This table compares Takeda Pharmaceutical and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Elanco Animal Health-8.45%3.43%2.04%

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Takeda Pharmaceutical and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.77$407.02 million$1.789.53
Elanco Animal Health$3.07 billion4.96$67.90 million$1.0630.42

Takeda Pharmaceutical has higher revenue and earnings than Elanco Animal Health. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Takeda Pharmaceutical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Summary

Takeda Pharmaceutical beats Elanco Animal Health on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Alexion Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals015402.21
Elanco Animal Health23702.42

Alexion Pharmaceuticals currently has a consensus price target of $159.3158, suggesting a potential downside of 7.27%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Elanco Animal Health-8.45%3.43%2.04%

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Alexion Pharmaceuticals and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.61$2.40 billion$9.7417.64
Elanco Animal Health$3.07 billion4.96$67.90 million$1.0630.42

Alexion Pharmaceuticals has higher revenue and earnings than Elanco Animal Health. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Elanco Animal Health on 11 of the 14 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for BeiGene and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
Elanco Animal Health23702.42

BeiGene currently has a consensus price target of $317.1250, suggesting a potential upside of 4.55%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given BeiGene's stronger consensus rating and higher probable upside, research analysts clearly believe BeiGene is more favorable than Elanco Animal Health.

Profitability

This table compares BeiGene and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Elanco Animal Health-8.45%3.43%2.04%

Institutional & Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BeiGene and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million64.96$-948,630,000.00($15.80)-19.20
Elanco Animal Health$3.07 billion4.96$67.90 million$1.0630.42

Elanco Animal Health has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Summary

Elanco Animal Health beats BeiGene on 8 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Elanco Animal Health (NYSE:ELAN) are both large-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Royalty Pharma and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Elanco Animal Health23702.42

Royalty Pharma currently has a consensus price target of $51.8750, suggesting a potential upside of 25.03%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Royalty Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Royalty Pharma is more favorable than Elanco Animal Health.

Profitability

This table compares Royalty Pharma and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Elanco Animal Health-8.45%3.43%2.04%

Institutional & Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Royalty Pharma and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Elanco Animal Health$3.07 billion4.96$67.90 million$1.0630.42

Elanco Animal Health has higher revenue and earnings than Royalty Pharma.

Summary

Elanco Animal Health beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.


Elanco Animal Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$212.90-1.0%$55.11 billion$4.16 billion26.88
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.34-1.1%$53.82 billion$7.86 billion18.36Earnings Announcement
Insider Selling
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.96-0.5%$53.52 billion$30.20 billion56.54Upcoming Earnings
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$171.81-0.8%$37.97 billion$4.99 billion40.14Analyst Revision
BeiGene logo
BGNE
BeiGene
1.3$303.32-2.9%$27.81 billion$428.21 million-15.01Earnings Announcement
Analyst Report
Analyst Revision
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$41.49-1.3%$25.19 billionN/A0.00
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.24-0.4%$24.42 billion$804.57 million28.87Earnings Announcement
Analyst Revision
CureVac logo
CVAC
CureVac
0.7$105.79-5.1%$19.77 billionN/A0.00Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$86.24-2.0%$19.38 billion$1.30 billion23.56Earnings Announcement
Catalent logo
CTLT
Catalent
1.7$104.80-2.6%$17.85 billion$3.09 billion66.75Earnings Announcement
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$128.63-2.1%$15.12 billion$219.75 million-16.43
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.39-1.8%$13.96 billion$1.70 billion17.48Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$149.45-5.8%$13.33 billion$12.98 million-49.32
Grifols logo
GRFS
Grifols
1.3$18.60-2.0%$12.79 billion$5.71 billion16.61Earnings Announcement
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.20-1.6%$12.01 billion$2.32 billion59.67
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.25-1.5%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.10-0.9%$10.02 billion$2.16 billion55.55Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
2.1$27.53-2.0%$9.87 billion$8.60 billion-5.05
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.82-3.7%$9.23 billionN/A0.00News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$189.88-2.9%$8.51 billion$1.45 billion17.96Earnings Announcement
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$147.63-2.5%$7.58 billion$3.34 million-19.17Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$109.25-4.8%$7.37 billion$103.71 million-24.89Earnings Announcement
Analyst Report
Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$130.07-2.2%$6.99 billion$14.98 million-15.84Upcoming Earnings
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$46.47-3.4%$6.94 billion$40.56 million-13.63Earnings Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.10-0.4%$6.88 billion$87.99 million-78.69Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$43.12-0.4%$5.76 billion$4.84 billion-718.55
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.03-6.5%$5.59 billion$380.83 million-8.96Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.21-2.9%$5.38 billion$66.51 million17.01
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$37.90-6.1%$5.36 billion$150,000.00-17.88News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.24-0.8%$5.11 billion$1.12 billion75.50Earnings Announcement
Allakos logo
ALLK
Allakos
1.7$94.95-6.3%$5.08 billionN/A-34.65News Coverage
Galapagos logo
GLPG
Galapagos
1.3$73.54-2.0%$4.82 billion$1.00 billion-11.14Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.6$64.01-6.8%$4.48 billion$85.54 million0.00News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.89-0.2%$4.38 billion$6.87 million-7.24Earnings Announcement
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$69.34-3.0%$4.30 billionN/A-5.65Earnings Announcement
News Coverage
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$56.74-4.5%$4.08 billion$4.31 million-1.96
LEGN
Legend Biotech
1.3$29.34-2.6%$3.90 billion$64.39 million0.00
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.75-0.1%$3.90 billion$117.91 million-11.31
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$63.27-2.4%$3.84 billion$806.43 million-8.96Earnings Announcement
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$24.99-5.0%$3.72 billion$204.89 million-31.24
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.15-4.3%$3.63 billionN/A-6.08
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.73-1.9%$3.60 billion$114.62 million-7.96Earnings Announcement
Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$21.65-1.7%$3.47 billion$1.17 billion-47.05High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.02-0.2%$3.37 billion$339.08 million-12.22Earnings Announcement
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$111.76-2.8%$3.29 billionN/A-55.60Earnings Announcement
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$59.87-2.9%$3.21 billion$1.11 billion19.25
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$62.93-3.2%$3.09 billionN/A-17.93Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$84.76-0.4%$3.07 billion$26.52 million-7.47Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$61.39-3.6%$3.01 billion$42.98 million-23.98
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.